IceCure adds Adventist Health Glendale as enrolling site for ChoICE breast cancer cryoablation study
ICCM•Adventist Health Glendale joins ChoICE study
- IceCure Medical added Adventist Health Glendale as the first U.S. site enrolling patients in its post-marketing ChoICE study of ProSense for low-risk breast cancer.
- No study results were presented; the trial will collect real-world evidence to support broader clinical adoption and patient access.
- The study targets up to 400 patients across multiple U.S. sites, extending data generation following FDA marketing authorization in October 2025.
- Adventist Health Glendale will be led by breast surgeon Dennis Holmes, a researcher in breast cancer cryoablation.
Related News
RedCloud signs open-weights AI letter, plans to specialize models on $6.9 billion FMCG trading data in-house
RCT•
PSQ Holdings partners with Rayon AI to embed exclusive payments, consumer credit in firearms e-commerce platform
PSQH•
